Abstract: A composition comprising at least two different strains of isolated bacteriophages, each capable of infecting a bacteria of the species Klebsiella pneumoniae, wherein at least one of said at least two different strains of isolated bacteriophages has a genomic nucleic acid sequence at least 90% identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-30. Uses thereof are also disclosed.
Type:
Application
Filed:
January 20, 2022
Publication date:
March 7, 2024
Applicant:
Biomx Ltd.
Inventors:
Eyal WEINSTOCK, Iddo Nadav WEINER, Maya KAHAN-HANUM, Efrat KHABRA, Noa BEN-YISHAI, Dana INBAR, Rotem EDGAR
Abstract: A method of treating a disease associated with Fusobacterium nucleatum infection in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one isolated bacteriophage capable of infecting a Fusobacterium nucleatum bacterial species, wherein said at least one bacteriophage has a genomic nucleic acid sequence at least 85% identical to the nucleic acid sequence as set forth in SEQ ID NOs: 1-7 or 15-20. Compositions for treating the disease are also disclosed.
Abstract: Disclosed herein are bacteriophage compositions and therapeutic uses thereof. The disclosure also relates to bacteriophage that are capable of lysing Klebsiella bacterial strains, e.g., strains that are associated with inflammatory bowel disease, and thereby capable of modulating disease.
Type:
Application
Filed:
March 6, 2020
Publication date:
May 19, 2022
Applicants:
Keio University, Biomx Ltd.
Inventors:
Kenya HONDA, Koji ATARASHI, Seiko NARUSHIMA, Efrat KHABRA, Hava BEN DAVID, Eyal WEINSTOCK, Yulia MATIUHIN, Naomi Bluma ZAK
© 2024 Justia
